Medical device maker Danaher Corp.’s COVID-19 blood test for detecting if a person had ever been infected with the new coronavirus received emergency use clearance from the U.S. Food and Drug Administration.
LabCorp launched a new test that could assess the capacity of antibodies in patient plasma to inhibit the novel coronavirus.
Siemens Healthineers stands ready to ramp up production of the company’s antibody test to more than 50 million per month from June 2020 as governments across the world are keen to identify those who may have developed immunity to the coronavirus.
iSpecimen will supply the U.S. Centers for Disease Control and Prevention (CDC) with serum samples from subjects who have previously tested positive for SARS-CoV-2, the virus that causes COVID-19.
Roche won emergency approval from the U.S. Food and Drug Administration in for an antibody test to determine whether people have ever been infected with the coronavirus.
While the world waits for a vaccine against SARS-CoV-2 – the novel coronavirus that causes COVID-19 – one likely control and exit strategy is testing for immunity, or an antibody test.
The U.S. Food and Drug Administration approved the first blood test that looks for the antibodies against the novel coronavirus that causes COVID-19.
As the COVID-19 pandemic spreads around the world, researchers and public health experts are casting about for older vaccines and antiviral drugs that might be used to treat the disease caused by the novel coronavirus SARS-CoV-2. Researchers in Australia are studying an older treatment, a vaccine once used to prevent tuberculosis called the bacillus Calmette-Guerin (BCG), which has been used for about 100 years.
Jeffrey Bluestone, the noted scientific researcher and pioneer in understanding T-cell activation and immune tolerance in cancer patients, stepped down from his role as chief executive of the Parker Institute for Cancer Immunotherapy to launch Sonoma Biotherapeutics.